Lisanti Capital Growth Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$10.6M |
| 2 |
Rapid7
RPD
|
+$9.7M |
| 3 |
Papa John's
PZZA
|
+$9.57M |
| 4 |
BLD
TopBuild
BLD
|
+$8.63M |
| 5 |
PYCR
Paycor HCM, Inc. Common Stock
PYCR
|
+$7.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Asana
ASAN
|
+$17.4M |
| 2 |
CareDx
CDNA
|
+$14.9M |
| 3 |
Surgery Partners
SGRY
|
+$11.8M |
| 4 |
Azenta
AZTA
|
+$11.5M |
| 5 |
SiTime
SITM
|
+$11.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.4% |
| 2 | Healthcare | 21.09% |
| 3 | Industrials | 17.66% |
| 4 | Consumer Discretionary | 15.18% |
| 5 | Financials | 5.41% |
Similar funds
Lisanti Capital Growth's Q3 2021 Portfolio in Review
As of Q3 2021, Lisanti Capital Growth held 174 positions worth $678M, down 16% from $808M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Lisanti Capital Growth withdrew a net $178M in Q3 2021, closing 45 positions and reducing 49 holdings. Its most notable exit was CareDx, an estimated $14.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 26% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Lisanti Capital Growth opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $11.8M.
- Lisanti Capital Growth's largest Q3 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 85,280 shares worth $11.8M.
- Lisanti Capital Growth added most to Allegiant Air in Q3 2021, an estimated $3.11M increase.
- Lisanti Capital Growth's biggest Q3 2021 reduction was Asana, cutting an estimated $17.4M.
- Lisanti Capital Growth fully exited CareDx in Q3 2021, selling an estimated $14.9M.
- Lisanti Capital Growth's ten largest holdings make up 21% of its $678M portfolio in Q3 2021.
- Lisanti Capital Growth opened 44 new positions and closed 45 in Q3 2021.
- Lisanti Capital Growth's portfolio value fell 16% quarter-over-quarter to $678M.
Based on Lisanti Capital Growth's 13F filing for Q3 2021, filed 3 Nov 2021.